Public Charity

FOUNDATION FOR ANGELMAN SYNDROME THERAPEUTICS

FOUNDATION FOR ANGELMAN SYNDROME THERAPEUTICS is a nonprofit organization categorized as Public Charity based in AUSTIN, TX. Its most recent IRS filing (2024) reports revenue of $5.4M, expenses of $10.4M, total assets of $44.9M. Imperigo tracks 84 reported grant relationships connected to this organization totaling approximately $2.7M.

EIN: 263160079 AUSTIN, TX Fund Raising & Fund Distribution NTEE: H12 Latest filing: 2024
Total Revenue$5.4M
Total Expenses$10.4M
Total Assets$44.9M
Grant Records84
Funding Total$2.7M
Filing Years2019–2024

Mission

ANGELMAN SYNDROME (AS) IS A NEURODEVELOPMENTAL DISORDER CHARACTERIZED BY GLOBAL DEVELOPMENT DELAYS AND SEVERE SPEECH IMPAIRMENT. A FEW INDIVIDUALS WITH AS DEVELOP FUNCTIONAL SPEECH, BUT MOST COMMUNICATE THROUGH A MIXTURE OF GESTURES, EYE GAZE, ADAPTED SIGN LANGUAGE AND AUGUMENTATIVE COMMUNICATION DEVICES. INDIVIDUALS WITH AS HAVE DEVELOPMENT DELAY AND INTELLECTUAL DISABILITIES. CURRENT RESEARCH SUGGESTS THAT NEURONAL DEVELOPMENT OCCURS CORRECTLY IN AS, BUT NEURONAL FUNCTIONING IS IMPAIRED. THIS NEURONAL IMPAIRMENT IMPACTS THE INDIVIDUAL'S ABILITY TO LEARN IN THAT SKILLS ARE ACQUIRED LESS RAPIDLY THAN IN AGE-MATCHED PEERS. THE FOUNDATION FOR ANGELMAN SYNDROME THERAPEUTICS IS AN ORGANIZATION OF FAMILIES AND PROFESSIONALS DEDICATED TO FINDING A CURE FOR AS AND RELATED DISORDERS THROUGH THE FUNDING OF AN AGRESSIVE RESEARCH AGENDA, EDUCATION, ADVOCACY, AND COMMUNITY SUPPORT. FAST IS COMMITTED TO ASSISTING INDIVIDUALS LIVING WITH AS TO REALIZE THEIR FULL POTENTIAL AND QUALITY OF LIFE.

Where $100 goes at Foundation for Angelman Syndrome Therapeutics

How Foundation for Angelman Syndrome Therapeutics divides every $100 it spends, from its own Form 990 filings, averaged across 7 years.

$92 Programs the work itself
$5 Management running the organization
$3 Fundraising raising the next dollar

Inside the $92 for programs

$55
As is a rare disorder
60% of program spending
$37
Fast's primary goal is to advance research leading to a cure for as in the form of providing grants to universities to perform research and testing
40% of program spending
Share on LinkedIn Share on Facebook
Add this to your website

Source: Form 990 filings with the IRS, latest fiscal year 2024. Shares are from the organization's reported expenses. Data by Imperigo; not affiliated with the IRS.

Officers & Directors

PRESIDENT/CEO Alana Newhouse
CHIEF SCIENCE OFFICER Allyson Berent
SECRETARY Amelia Beatty
DIRECTOR Ben O'connor
TRESURER Guy Shapiral
DIRECTOR John Schlueter

Officer compensation and complete director data available with membership.

Top Grant Purposes

General Support
$2,102,138 62 grants
Health & Medicine
$480,659 13 grants
Human & Social Services
$77,500 2 grants
Religion & Spirituality
$41,000 1 grant
Research & Policy
$10,000 1 grant

Financial Trends

Year Revenue Expenses Assets
2024 $5.4M $10.4M $44.9M
2023 $6.5M $23.2M $58.4M
2022 $52.5M $8.9M $63.1M
2020 $9.4M $3.1M $18.3M
2019 $5.7M $4.6M $12.0M

Between 2019 and 2024, reported annual revenue declined from $5.7M to $5.4M (-6%), with total assets most recently reported at $44.9M.

Interactive year-over-year charts and full filing details available with membership.

See the full picture for FOUNDATION FOR ANGELMAN SYNDROME THERAPEUTICS

Complete financials, all 84 grant records, officer compensation, year-over-year trend charts, a geographic grant map, and data exports — across 880,000+ organizations.

Full Financial History Complete Grant Activity Officer Compensation Year-over-Year Charts Geographic Grant Map Data Exports
7-day free trial Cancel any time